drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (adoptive T-cell therapy)
drug_description
Ex vivo engineered/expanded autologous T cells administered intravenously for antigen-directed adoptive cell therapy. These cells recognize a tumor-associated antigen on GI cancers (esophageal, gastric, pancreatic, colorectal) and mediate cytotoxic killing and cytokine-driven immune activation; in vivo expansion and persistence are assessed.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Adoptive Immunotherapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered ex vivo to express a chimeric antigen receptor that recognizes a tumor‑associated antigen on gastrointestinal tumor cells. Upon antigen engagement, CAR signaling (CD3ζ with co‑stimulatory domains) activates the T cells to mediate targeted cytotoxic killing and cytokine release, with in vivo expansion and persistence supporting ongoing anti‑tumor activity.
drug_name
BGT007H cells
nct_id_drug_ref
NCT06152757